logo-loader
viewOcado Group PLC

Ocado shares jump as Goldman Sachs calls its deal with Kroger ‘transformational’

Goldman Sachs upgraded Ocado’s rating to ‘buy’ from ‘neutral’ and set its price target at 1,160p

Ocado delivery truck
In morning trading, Ocado’s shares rose 3.4% to 1,033.5p

Ocado Group PLC (LON:OCDO) shares rose on Monday as Goldman Sachs upgraded its rating after calling UK online grocer’s partnership with US retail giant Kroger Co (NYSE:KR) “transformational”.

Goldman Sachs upgraded Ocado’s rating to ‘buy’ from ‘neutral’ and set its price target at 1,160p.

READ: Ocado and Kroger looking to transform US grocer sector

In a note to clients, analysts at Goldman Sachs said Ocado’s partnership with Kruger was ‘transformational’ both in the number of distribution centres Kroger is looking to start building and in the validation of Ocado’s Smart Platform (OSP) as an online grocery solution with a global addressable market.

The analysts said: “Though the stock price moved materially to reflect this, our analysis at a local market level points to a US opportunity more than double Kroger’s initial commitment, with the economics to Kroger clear on our calculations.”

“Finally, our updated work on Ocado’s core business points to a UK retail business worth 700p, with further potential upside from further automation of Ocado’s CFCs,“ the analysts concluded.

In morning trading, Ocado’s shares rose 3.4% to 1,033.5p. 

Quick facts: Ocado Group PLC

Price: 1204.5 GBX

AIM:OCDO
Market: AIM
Market Cap: £8.54 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Summit Therapeutics' Glyn Edwards talks US$50mln backing and ridinilazole...

Summit Therapeutics PLC's (LON:SUMM, NASDAQ:SMMT) CEO Glyn Edwards sat down with Proactive London's Andrew Scott following the news of a US$50mln funding deal with biotech billionaire Bob Duggan. The investment will help get the company’s next-generation antibiotic through phase III clinical...

9 hours, 16 minutes ago

2 min read